PML is a direct p53 target that modulates p53 effector functions

Molecular Cell

Volumn 13, Issue 4, 2004, Pages 523-535

  De Stanchina, Elisa ^a   Querido, Emmanuelle ^a   Narita, Masako ^a   Davuluri, Ramana V ^b   Pandolfi, Pier Paolo ^c   Ferbeyre, Gerardo ^d   Lowe, Scott W ^a  

^a Simons Center for Quantitative Biology   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL AGING; CONTROLLED STUDY; DNA DAMAGE; GENE IDENTIFICATION; GENE TARGETING; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; ONCOGENE; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN TARGETING; REPORTER GENE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL AGING; CELL LINE; CELL SURVIVAL; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; GENES, REPORTER; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 1542285168     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(04)00062-0     Document Type: Article

References (57)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 318:1985;533-538.
2. Attardi L.D., Lowe S.W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:1996;3693-3701.
3. Bett A.J., Haddara W., Prevec L., Graham F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA. 91:1994;8802-8806.
4. Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.G., Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 21:2002;3358-3369.
5. Borden K.L.B. Pondering the promyelocytic leukemia protein (PML) puzzle. possible functions for PML nuclear bodies Mol. Cell. Biol. 22:2002;5259-5269.
6. Campisi J. Cancer and ageing. rival demons? Nat. Rev. Cancer. 3:2003;339-349.
7. Chelbi-Alix M.K., Pelicano L., Quignon F., Koken M.H., Venturini L., Stadler M., Pavlovic J., Degos L., de The H. Induction of the PML protein by interferons in normal and APL cells. Leukemia. 9:1995;2027-2033.
8. de Stanchina E., McCurrach M.E., Zindy F., Shieh S., Ferbeyre G., Samuelson A.V., Prives C., Roussel M.F., Sherr C.J., Lowe S.W. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev. 12:1998;2434-2442.
9. Dyck J.A., Maul G.G., Miller W.H. Jr., Chen J.D., Kakizuka A., Evans R.M. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 76:1994;333-343.
10. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 15:1999;2658-2669.
11. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
12. Everett R.D. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene. 20:2001;7266-7273.
13. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14:2000;2015-2027.
14. Ferbeyre G., de Stanchina E., Lin A.W., Querido E., McCurrach M.E., Hannon G.J., Lowe S.W. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22:2002;3497-3508.
15. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
16. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., Jensen K., Pandolfi P.P., Will H., Schneider C., Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:2000;6185-6195.
17. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene. 22:2003;9030-9040.
18. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:2000;730-736.
19. Gurrieri, C., Nafa, K., Merghoub, T., Bernardi, R., Capodieci, P., Biondi, A., Nimer, S.D., Douer, D., Cordon-Cardo, C., Gallagher, R., et al. (2003). Mutations of the PML tumor suppressor gene in APL. Blood, in press. Published online November 20, 2003. 10.1182/blood.2003072200
20. Hemann M.T., Fridman J.S., Zilfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., Hannon G.J., Lowe S.W. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33:2003;396-400.
21. Hermeking H., Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 265:1994;2091-2093.
22. Hoh J., Jin S., Parrado T., Edington J., Levine A.J., Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA. 99:2002;8467-8472.
23. Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 8:1993;3411-3416.
24. Kunz C., Peble R.S., Otte J., von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23:1995;3710-3717.
25. Kurki S., Latonen L., Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell Sci. 116:2003;3917-3925.
26. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:1998;3008-3019.
27. Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., Haupt Y. PML protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem. 278:2003;33134-33141.
28. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
29. McCurrach M.E., Connor T., Knudson C.M., Korsmeyer S.J., Lowe S.W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;2345-2349.
30. Melnick A., Licht J.D. Deconstructing a disease. RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia Blood. 93:1999;3167-3215.
31. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell. 7:2001;683-694.
32. Oren M. Decision making by p53. life, death and cancer Cell Death Differ. 10:2003;431-442.
33. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 395:1998;125-126.
34. Pearson M., Pelicci P.G. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene. 20:2001;7250-7256.
35. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P.et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:2000;207-210.
36. Piazza F., Gurrieri C., Pandolfi P.P. The theory of APL. Oncogene. 20:2001;7216-7222.
37. Prives C. Signaling to p53. breaking the Mdm2-p53 circuit Cell. 95:1998;5-8.
38. Quignon F., De Bels F., Koken M., Feunteun J., Ameisen J.C., de The H. PML induces a novel caspase-independent death process. Nat. Genet. 20:1998;259-265.
39. Regad T., Chelbi-Alix M.K. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene. 20:2001;7274-7286.
40. Rego E.M., Wang Z.G., Peruzzi D., He L.Z., Cordon-Cardo C., Pandolfi P.P. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193:2001;521-529.
41. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell. 108:2002;165-170.
42. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:1999;2670-2677.
43. Seker H., Rubbi C., Linke S.P., Bowman E.D., Garfield S., Hansen L., Borden K.L.B., Milner J., Harris C.C. UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene. 22:2003;1620-1628.
44. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4A. Cell. 88:1997;593-602.
45. Stadler M., Chelbi-Alix M.K., Koken M.H.M., Venturini L., Lee C., Saïb A., Quignon F., Pelicano L., Guillemin M.-C., Schindler C.et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene. 11:1995;2565-2573.
46. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K.et al. Integration of interferon-α/β signalling to p-53 responses in tumor suppression and antiviral defence. Nature. 424:2003;516-523.
47. Thornborrow E.C., Patel S., Mastropietro A.E., Schwartzfarb E.M., Manfredi J.J. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene. 21:2002;990-999.
48. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 302:2003;1036-1038.
49. Vogelstein B., Lane D., Levine A. Surfing the p53 network. Nature. 408:2000;307-310.
50. Wang Z.G., Delva L., Gaboli M., Rivi R., Giorgio M., Cordon-Cardo C., Grosveld F., Pandolfi P.P. Role of PML in cell growth and the retinoic acid pathway. Science. 279:1998;1547-1551. a.
51. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:1998;266-272. b.
52. Wei X., Yu Z.K., Ramalingam A., Grossman S.R., Yu J.H., Bloch D.B. Physical and functional interactions between PML and MDM2. J. Biol. Chem. 278:2003;29288-29297.
53. Yang S., Kuo C., Bisi J.E., Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4:2002;865-870.
54. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7:2001;673-682.
55. Zhong S., Salomoni P., Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:2000;E85-E90.
56. Zhu J., Koken M.H., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y., Chen Z., de The H. Arsenic-induced PML targeting onto nuclear bodies. implications for the treatment of acute promyelocytic leukemia Proc. Natl. Acad. Sci. USA. 94:1997;3978-3983.
57. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:1998;2997-3007.